KR20190138650A - 반흔성 안구 염증성 장애의 치료를 위한 코버신 - Google Patents

반흔성 안구 염증성 장애의 치료를 위한 코버신 Download PDF

Info

Publication number
KR20190138650A
KR20190138650A KR1020197031685A KR20197031685A KR20190138650A KR 20190138650 A KR20190138650 A KR 20190138650A KR 1020197031685 A KR1020197031685 A KR 1020197031685A KR 20197031685 A KR20197031685 A KR 20197031685A KR 20190138650 A KR20190138650 A KR 20190138650A
Authority
KR
South Korea
Prior art keywords
seq
ala
coversin
asp
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031685A
Other languages
English (en)
Korean (ko)
Inventor
윈 에이치 웨스턴-데이비스
Original Assignee
볼루션 이뮤노 파마슈티컬스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706398.3A external-priority patent/GB201706398D0/en
Application filed by 볼루션 이뮤노 파마슈티컬스 에스에이 filed Critical 볼루션 이뮤노 파마슈티컬스 에스에이
Publication of KR20190138650A publication Critical patent/KR20190138650A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197031685A 2017-04-21 2018-04-20 반흔성 안구 염증성 장애의 치료를 위한 코버신 Ceased KR20190138650A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706398.3A GB201706398D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706398.3 2017-04-21
GB1706406.4 2017-04-21
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Publications (1)

Publication Number Publication Date
KR20190138650A true KR20190138650A (ko) 2019-12-13

Family

ID=62028030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031685A Ceased KR20190138650A (ko) 2017-04-21 2018-04-20 반흔성 안구 염증성 장애의 치료를 위한 코버신

Country Status (8)

Country Link
US (1) US20210113658A1 (enExample)
EP (1) EP3612206A1 (enExample)
JP (2) JP7153669B2 (enExample)
KR (1) KR20190138650A (enExample)
CN (1) CN110831617A (enExample)
AU (1) AU2018253960A1 (enExample)
CA (1) CA3060331A1 (enExample)
WO (1) WO2018193120A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
JP7736925B2 (ja) 2022-05-18 2025-09-09 旭化成株式会社 樹脂組成物の製造方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP2010502687A (ja) * 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
EA200901211A1 (ru) * 2007-03-22 2010-04-30 Новартис Аг Антигены белка с5 и их применение
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
ES3044832T3 (en) * 2011-06-22 2025-11-27 Apellis Pharmaceuticals Inc Methods of treating chronic disorders with complement inhibitors
US20170014487A1 (en) * 2014-03-04 2017-01-19 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) * 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Also Published As

Publication number Publication date
CN110831617A (zh) 2020-02-21
WO2018193120A1 (en) 2018-10-25
JP7153669B2 (ja) 2022-10-14
AU2018253960A1 (en) 2019-10-31
US20210113658A1 (en) 2021-04-22
JP2022188170A (ja) 2022-12-20
JP2020517643A (ja) 2020-06-18
EP3612206A1 (en) 2020-02-26
CA3060331A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
KR20190138650A (ko) 반흔성 안구 염증성 장애의 치료를 위한 코버신
KR102656199B1 (ko) 자가면역 수포 질환의 치료를 위한 코버신
RU2689607C2 (ru) миРНК И ИХ ПРИМЕНЕНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА ORAI1
JP2012516694A (ja) 補体阻害物質としての改変omci
JP2018526412A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
CN114072206B (zh) 治疗方法
JP2022542889A (ja) ドライアイ疾患のためのtsg6ポリペプチドフラグメント
US20050090466A1 (en) Inhibitors of PACE4 for the treatment of arthritis
EP1206942A1 (en) Water channel opener compositions and medicinal compositions for ophthalmic use
JP2001172190A (ja) 乳酸蓄積抑制剤
DK2061501T3 (en) METHOD OF TREATING RESPIRATORY DISORDERS
FR2761362A1 (fr) Polypeptide purifie de l'epiderme et son utilisation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210419

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230516

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230516

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I